Diabetes Conference-NFOD 2026

Gene therapy represents a promising frontier in diabetes treatment, particularly for Type 1 diabetes, by aiming to restore or replace dysfunctional beta cells and modulate immune responses. Innovative molecular approaches target genetic pathways to enhance insulin production, protect pancreatic cells, and improve glucose regulation. Research is also exploring gene editing technologies such as CRISPR to correct mutations linked to diabetes susceptibility. While still largely in preclinical and early clinical stages, these therapies hold potential for long-term disease modification and personalized treatment strategies. Advancements in gene therapy could transform the management of diabetes, offering hope for more effective, durable, and targeted interventions that move beyond conventional pharmacological approaches.